Boya Bio-pharmaceutical Group Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Boya Bio-pharmaceutical Group Co Ltd with three other
companies in this sector in China:
Shenzhen Kangtai Biological Products Co Ltd
sales of 2.02 billion Chinese Renmimbi [US$287.00 million]
of which 100%
was Biological products),
Beijing SL Pharmaceutical Co Ltd
(2.17 billion Chinese Renmimbi [US$308.58 million]
of which 99%
was Pharmaceuticals Industry), and
Tonghua Dongbao Medicines Company Limited
(2.69 billion Chinese Renmimbi [US$382.65 million]
of which 87%
Boya Bio-pharmaceutical Group Co Ltd reported sales of 2.45 billion Chinese Renmimbi (US$348.99 million)
December of 2018.
increase of 67.8%
versus 2017, when the company's sales were 1.46 billion Chinese Renmimbi.
Sales at Boya Bio-pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2013, sales have increased a total of 899%).
Sales of Drug Distribution saw an increase
that was more than double the company's growth rate: sales were up
551.4% in 2018, from
85.13 million Chinese Renmimbi to 554.55 million Chinese Renmimbi.